Bruce Cozadd, Jazz Pharmaceuticals CEO
Zymeworks sings to the tune of $325M with Jazz opt-in for HER2 cancer drug
Zymeworks is capping a rocky year with a committed partner.
After announcing it would dole out $50 million to become the second partner on Zymeworks’ …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
